Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cue Biopharma (CUE) EBITDA (2017 - 2025)

Cue Biopharma (CUE) has disclosed EBITDA for 9 consecutive years, with $23.0 million as the latest value for Q4 2025.

  • Quarterly EBITDA rose 342.72% to $23.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$5.1 million through Dec 2025, up 87.37% year-over-year, with the annual reading at -$5.5 million for FY2025, 86.52% up from the prior year.
  • EBITDA hit $23.0 million in Q4 2025 for Cue Biopharma, up from -$7.4 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $23.0 million in Q4 2025 to a low of -$14.6 million in Q4 2022.
  • Historically, EBITDA has averaged -$9.7 million across 5 years, with a median of -$11.7 million in 2022.
  • Biggest five-year swings in EBITDA: plummeted 74.09% in 2022 and later soared 342.72% in 2025.
  • Year by year, EBITDA stood at -$8.4 million in 2021, then tumbled by 74.09% to -$14.6 million in 2022, then grew by 7.96% to -$13.4 million in 2023, then grew by 29.31% to -$9.5 million in 2024, then surged by 342.72% to $23.0 million in 2025.
  • Business Quant data shows EBITDA for CUE at $23.0 million in Q4 2025, -$7.4 million in Q3 2025, and -$8.5 million in Q2 2025.